Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma

Trial Profile

An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2019

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms DAWN
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 Dec 2018 Results of the biomarker analysis assessing whether somatic mutations could be used to identify FL patients who responded to ibrutinib, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 31 May 2018 Primary endpoint (Overall response rate) has not been met, according to results published in the Journal of Clinical Oncology.
    • 31 May 2018 Results (n=110) published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top